Overview of results for primary and secondary endpoints
| PFS median (95% CI), mo | OS median (95% CI), mo | ORR, % (95% CI) | DOR median (95% CI), mo | |
|---|---|---|---|---|
| Placebo BID and carbo/paclitaxel (N = 53) | 4.2 (3.1–5.6) | 9.1 (5.4–12.3) | 32.1 (19.9–46.3) | 4.3 (2.8–NA) |
| Squamous (n = 25) | 4.1 (2.8–NA) | 8.4 (5.0–12.9) | ||
| Nonsquamous (n = 28) | 5.0 (2.8–5.7) | 11.1 (4.8–14.6) | ||
| Veliparib BID and carbo/paclitaxel (N = 105) | 5.8 (4.3–6.5) | 11.7 (8.8–13.7) | 32.4 (23.6–42.2) | 6.9 (4.5–7.0) |
| Squamous (n = 51) | 6.5 (4.4–8.4) | 10.3 (8.3–13.2) | ||
| Nonsquamous (n = 54) | 5.6 (2.8–6.4) | 12.8 (8.0–17.2) | ||
| HR (95%CI) | ||||
| All patients (N = 158) | 0.72 (0.45–1.15) | 0.80 (0.54–1.18) | 0.47 (0.16–1.42) | |
| Squamous (n = 76) | 0.54 (0.26–1.12) | 0.73 (0.43–1.24) | ||
| Nonsquamous (n = 82) | 0.87 (0.48–1.59) | 0.90 (0.51–1.58) | ||
| Adjusted HRa (95% CI) | ||||
| All patients (N = 158) | 0.56 (0.35–0.90) | 0.72 (0.49–1.07) | ||
| Squamous (n = 76) | 0.43 (0.20–0.94) | 0.70 (0.39–1.21) | ||
| Nonsquamous (n = 82) | 0.73 (0.39–1.36) | 0.77 (0.43–1.37) | ||
Abbreviation: carbo, carboplatin.
↵aHR adjusted for ECOG performance status and gender.